AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory above $24B by 2027. Cerevel and ImmunoGen acquisitions add neuroscience and oncology. Aesthetics business stable. Capital allocation disciplined with steady dividend growth. Re-rating possible as biosimilar cliff fades from narrative.
Signals scoped to US · Company-specific tagging coming soon.